, Volume 78, Issue 18, pp 1887–1901 | Cite as

Efficacy of Metformin Treatment with Respect to Weight Reduction in Children and Adults with Obesity: A Systematic Review

  • Y. E. Lentferink
  • C. A. J. Knibbe
  • M. M. J. van der VorstEmail author
Systematic Review



Obesity and its related complications are increasing health issues. Since generally only minor weight loss is obtained with lifestyle intervention, additional pharmacological therapies such as metformin are often used.


We conducted a systematic review to provide an overview of the efficacy of ≥ 6 months of metformin treatment in children and adults with respect to weight, insulin resistance, and progression toward type 2 diabetes mellitus (T2DM).


In September 2018, we searched PubMed, Embase, and the Cochrane Library for studies published in English using the keywords metformin, obesity/overweight, and weight loss. Prospective studies reporting weight/body mass index (BMI) as a primary or secondary outcome in patients with overweight/obesity with ≥ 6 months’ metformin treatment were included. Included subjects were children and adults with overweight/obesity who received ≥ 6 months of metformin and/or lifestyle intervention, and/or placebo and/or lifestyle intervention, and/or standard care. Studies were independently screened by two reviewers. Data were extracted by one and verified by the other reviewer, and both reviewers assessed the risk of bias using the Cochrane risk-of-bias tool.


Our review includes 15 pediatric and 14 adult studies. In children, after 6 months, more than half the studies reported a greater reduction in BMI with metformin versus controls. Only six studies had an intervention of > 6 months, and these studies found no further improvement in BMI in the metformin users, though their BMI was lower than that of controls. Three studies showed a significant improvement in insulin sensitivity in the metformin versus the control group. Adults using metformin experienced and maintained small decreases in weight irrespective of duration of intervention. In 11 of 14 studies, a greater reduction in weight/BMI was observed with metformin than with placebo. Progression toward T2DM was significantly reduced in adults using metformin, ranging from 7 to 31%. The safety and tolerability of metformin, withdrawal of participants, and comparison with other drugs were not taken into account.


The effects of metformin on weight/BMI vary, with smaller reductions in children than in adults. This could be because of differences in adherence, daily dosage, and insulin status. Metformin significantly reduced the progression toward T2DM in adults. Therefore, metformin should be considered as a treatment for obesity and its related complications.


Compliance with Ethical Standards

Conflict of interest

Y. Lentferink, C. Knibbe, and M. van der Vorst have no conflicts of interest that are directly relevant to the content of this article.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors. Formal consent was not required for this type of study.


No sources of funding were used to conduct this study or prepare this manuscript.

Supplementary material

40265_2018_1025_MOESM1_ESM.docx (14 kb)
Supplementary material 1 (DOCX 13 kb)


  1. 1.
    NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults. Lancet. 2017;390(10113):2627–42.CrossRefGoogle Scholar
  2. 2.
    NCD Risk Factor Collaboration (NCD-RisC). Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19.2 million participants. Lancet. 2016;387(10026):1377–96.CrossRefGoogle Scholar
  3. 3.
    World Health Organisation, Obesity and overweight. 2017;2018(May).Google Scholar
  4. 4.
    Kelly AS, Barlow SE, Rao G, et al. Severe obesity in children and adolescents: identification, associated health risks, and treatment approaches: a scientific statement from the American Heart Association. Circulation. 2013;128(15):1689–712.PubMedCrossRefGoogle Scholar
  5. 5.
    Hales CM, Fryar CD, Carroll MD, Freedman DS, Ogden CL. Trends in obesity and severe obesity prevalence in US youth and adults by sex and age, 2007–2008 to 2015–2016. JAMA. 2018;319(16):1723–5.PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Kim DD, Basu A. Estimating the medical care costs of obesity in the United States: systematic review, meta-analysis, and empirical analysis. Value Health. 2016;19(5):602–13.PubMedCrossRefGoogle Scholar
  7. 7.
    Singh AS, Mulder C, Twisk JW, van Mechelen W, Chinapaw MJ. Tracking of childhood overweight into adulthood: a systematic review of the literature. Obes Rev. 2008;9(5):474–88.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Simmonds M, Burch J, Llewellyn A, et al. The use of measures of obesity in childhood for predicting obesity and the development of obesity-related diseases in adulthood: a systematic review and meta-analysis. Health Technol Assess. 2015;19(43):1–336.PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Kumar S, Kelly AS. Review of childhood obesity: from epidemiology, etiology, and comorbidities to clinical assessment and treatment. Mayo Clin Proc. 2017;92(2):251–65.PubMedCrossRefGoogle Scholar
  10. 10.
    Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity: a systematic and clinical review. JAMA. 2014;311(1):74–86.PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Carvajal R, Wadden TA, Tsai AG, Peck K, Moran CH. Managing obesity in primary care practice: a narrative review. Ann N Y Acad Sci. 2013;1281:191–206.PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Wadden TA, Volger S, Tsai AG, et al. Managing obesity in primary care practice: an overview with perspective from the POWER-UP study. Int J Obes (Lond). 2013;37(Suppl 1):S3–11.PubMedCentralCrossRefGoogle Scholar
  13. 13.
    Kelly AS, Fox CK. Pharmacotherapy in the management of pediatric obesity. Curr Diabetes Rep. 2017;17(8):5017–886.CrossRefGoogle Scholar
  14. 14.
    Williamson DA, Bray GA, Ryan DH. Is 5% weight loss a satisfactory criterion to define clinically significant weight loss? Obesity (Silver Spring). 2015;23(12):2319–20.CrossRefGoogle Scholar
  15. 15.
    Moyer VA, U.S. Preventive Services Task Force. Screening for and management of obesity in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157(5):373–8.PubMedPubMedCentralGoogle Scholar
  16. 16.
    National Institute of Diabetes and Digestive and Kidney Diseases. Prescription medications to treat overweight and obesity. 2016;2018(May).Google Scholar
  17. 17.
    Chao AM, Wadden TA, Berkowitz RI. The safety of pharmacologic treatment for pediatric obesity. Expert Opin Drug Saf. 2018;17(4):379–85.PubMedCrossRefGoogle Scholar
  18. 18.
    Khokhar A, Umpaichitra V, Chin VL, Perez-Colon S. Metformin use in children and adolescents with prediabetes. Pediatr Clin N Am. 2017;64(6):1341–53.CrossRefGoogle Scholar
  19. 19.
    Desilets AR, Dhakal-Karki S, Dunican KC. Role of metformin for weight management in patients without type 2 diabetes. Ann Pharmacother. 2008;42(6):817–26.PubMedCrossRefGoogle Scholar
  20. 20.
    Fazeli Farsani S, Souverein PC, Overbeek JA, et al. Long term trends in oral antidiabetic drug use among children and adolescents in the Netherlands. Br J Clin Pharmacol. 2015;80(2):294–303.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393–403.CrossRefGoogle Scholar
  22. 22.
    Knowler WC, Fowler SE, Diabetes Prevention Program Research Group, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009;374(9702):1677–86.PubMedCrossRefGoogle Scholar
  23. 23.
    Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. Lancet Diabetes Endocrinol. 2015;3(11):866–75.PubMedCentralCrossRefGoogle Scholar
  24. 24.
    Ramachandran A, Snehalatha C, Mary S, et al. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia. 2006;49(2):289–97.PubMedCrossRefGoogle Scholar
  25. 25.
    Andreadis EA, Katsanou PM, Georgiopoulos DX, et al. The effect of metformin on the incidence of type 2 diabetes mellitus and cardiovascular disease risk factors in overweight and obese subjects—the Carmos study. Exp Clin Endocrinol Diabetes. 2009;117(4):175–80.PubMedCrossRefGoogle Scholar
  26. 26.
    Iqbal Hydrie MZ, Basit A, Shera AS, Hussain A. Effect of intervention in subjects with high risk of diabetes mellitus in pakistan. J Nutr Metab. 2012;2012:867604.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Li CL, Pan CY, Lu JM, et al. Effect of metformin on patients with impaired glucose tolerance. Diabet Med. 1999;16(6):477–81.PubMedCrossRefGoogle Scholar
  28. 28.
    Higgins JPT, Altman DG, Sterne JAC (editors), Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Altman DG, Sterne JAC (editors), Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2011.Google Scholar
  29. 29.
    Atabek ME, Pirgon O. Use of metformin in obese adolescents with hyperinsulinemia: a 6-month, randomized, double-blind, placebo-controlled clinical trial. J Pediatr Endocrinol Metab. 2008;21(4):339–48.PubMedCrossRefGoogle Scholar
  30. 30.
    Clarson CL, Mahmud FH, Baker JE, et al. Metformin in combination with structured lifestyle intervention improved body mass index in obese adolescents, but did not improve insulin resistance. Endocrine. 2009;36(1):141–6.PubMedCrossRefGoogle Scholar
  31. 31.
    Freemark M, Bursey D. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics. 2001;107(4):E55.PubMedCrossRefGoogle Scholar
  32. 32.
    Kendall D, Vail A, Amin R, et al. Metformin in obese children and adolescents: the MOCA trial. J Clin Endocrinol Metab. 2013;98(1):322–9.PubMedCrossRefGoogle Scholar
  33. 33.
    Srinivasan S, Ambler GR, Baur LA, et al. Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. J Clin Endocrinol Metab. 2006;91(6):2074–80.PubMedCrossRefGoogle Scholar
  34. 34.
    Yanovski JA, Krakoff J, Salaita CG, et al. Effects of metformin on body weight and body composition in obese insulin-resistant children: a randomized clinical trial. Diabetes. 2011;60(2):477–85.PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Clarson CL, Brown HK, De Jesus S, et al. Effects of a comprehensive, intensive lifestyle intervention combined with metformin extended release in obese adolescents. Int Sch Res Notices. 2014;2014:659410.PubMedPubMedCentralGoogle Scholar
  36. 36.
    Love-Osborne K, Sheeder J, Zeitler P. Addition of metformin to a lifestyle modification program in adolescents with insulin resistance. J Pediatr. 2008;152(6):817–22.PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    Mauras N, DelGiorno C, Hossain J, et al. Metformin use in children with obesity and normal glucose tolerance—effects on cardiovascular markers and intrahepatic fat. J Pediatr Endocrinol Metab. 2012;25(1–2):33–40.PubMedPubMedCentralGoogle Scholar
  38. 38.
    Pastor-Villaescusa B, Canete MD, Caballero-Villarraso J, et al. Metformin for obesity in prepubertal and pubertal children: a randomized controlled trial. Pediatrics. 2017. (Epub 2017 Jun 12).PubMedCrossRefGoogle Scholar
  39. 39.
    Wiegand S, Allemand D, Hubel H, et al. Metformin and placebo therapy both improve weight management and fasting insulin in obese insulin-resistant adolescents: a prospective, placebo-controlled, randomized study. Eur J Endocrinol. 2010;163(4):585–92.PubMedCrossRefGoogle Scholar
  40. 40.
    Warnakulasuriya LS, Fernando MMA, Adikaram AVN, et al., Metformin in the management of childhood obesity: a randomized control trial. Child Obes 2018.Google Scholar
  41. 41.
    Wilson DM, Abrams SH, Aye T, et al. Metformin extended release treatment of adolescent obesity: a 48-week randomized, double-blind, placebo-controlled trial with 48-week follow-up. Arch Pediatr Adolesc Med. 2010;164(2):116–23.PubMedGoogle Scholar
  42. 42.
    van der Aa MP, Elst MA, van de Garde EM, van Mil EG, Knibbe CA, van der Vorst MM. Long-term treatment with metformin in obese, insulin-resistant adolescents: results of a randomized double-blinded placebo-controlled trial. Nutr Diabetes. 2016;6(8):e228.PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    Lentferink YE, van der Aa MP, van Mill EGAH, Knibbe CAJ, van der Vorst MMJ. Long-term metformin treatment in adolescents with obesity and insulin resistance, results of an open label extension study. Nutr Diabetes. 2018;8(1):47.PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    Lehtovirta M, Forsen B, Gullstrom M, et al. Metabolic effects of metformin in patients with impaired glucose tolerance. Diabet Med. 2001;18(7):578–83.PubMedCrossRefGoogle Scholar
  45. 45.
    Worsley R, Jane F, Robinson PJ, Bell RJ, Davis SR. Metformin for overweight women at midlife: a double-blind, randomized, controlled trial. Climacteric. 2015;18(2):270–7.PubMedCrossRefGoogle Scholar
  46. 46.
    Fontbonne A, Charles MA, Juhan-Vague I, BIGPRO Study Group, et al. The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. Diabetes Care. 1996;19(9):920–6.PubMedCrossRefGoogle Scholar
  47. 47.
    O’Brien MJ, Perez A, Scanlan AB, et al. PREVENT-DM comparative effectiveness trial of lifestyle intervention and metformin. Am J Prev Med. 2017;52(6):788–97.PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Schuster D, Gaillard T, Rhinesmith S, Habash D, Osei K. Impact of metformin on glucose metabolism in nondiabetic, obese African Americans: a placebo-controlled, 24-month randomized study. Diabetes Care. 2004;27(11):2768–9.PubMedCrossRefGoogle Scholar
  49. 49.
    Alibasic E, Ramic E, Alic A. Prevention of diabetes in family medicine. Mater Sociomed. 2013;25(2):80–2.PubMedPubMedCentralCrossRefGoogle Scholar
  50. 50.
    Seifarth C, Schehler B, Schneider HJ. Effectiveness of metformin on weight loss in non-diabetic individuals with obesity. Exp Clin Endocrinol Diabetes. 2013;121(1):27–31.PubMedGoogle Scholar
  51. 51.
    Cole TJ, Bellizzi MC, Flegal KM, Dietz WH. Establishing a standard definition for child overweight and obesity worldwide: international survey. BMJ. 2000;320(7244):1240–3.PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    Cole TJ, Faith MS, Pietrobelli A, Heo M. What is the best measure of adiposity change in growing children: BMI, BMI %, BMI z-score or BMI centile? Eur J Clin Nutr. 2005;59(3):419–25.PubMedCrossRefGoogle Scholar
  53. 53.
    Spear BA, Barlow SE, Ervin C, et al. Recommendations for treatment of child and adolescent overweight and obesity. Pediatrics. 2007;120(Suppl 4):S254–88.PubMedCrossRefGoogle Scholar
  54. 54.
    Electronic Medicines Compendium, Metformin. 2017;2018(May).Google Scholar
  55. 55.
    McDonagh MS, Selph S, Ozpinar A, Foley C. Systematic review of the benefits and risks of metformin in treating obesity in children aged 18 years and younger. JAMA Pediatr. 2014;168(2):178–84.PubMedCrossRefGoogle Scholar
  56. 56.
    van Rongen A, van der Aa MP, Matic M, et al.. Increased metformin clearance in overweight and obese adolescents: a Pharmacokinetic substudy of a randomized controlled trial. Paediatr Drugs. 2018.Google Scholar
  57. 57.
    Diabetes Prevention Program Research Group. Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care. 2012;35(4):731–7.CrossRefGoogle Scholar
  58. 58.
    Goran MI, Gower BA. Longitudinal study on pubertal insulin resistance. Diabetes. 2001;50(11):2444–50.PubMedCrossRefGoogle Scholar
  59. 59.
    Moran A, Jacobs DR Jr, Steinberger J, et al. Insulin resistance during puberty: results from clamp studies in 357 children. Diabetes. 1999;48(10):2039–44.PubMedCrossRefGoogle Scholar
  60. 60.
    Herman WH, Edelstein SL, Ratner RE, et al. Effectiveness and cost-effectiveness of diabetes prevention among adherent participants. Am J Manag Care. 2013;19(3):194–202.PubMedPubMedCentralGoogle Scholar
  61. 61.
    Tamborlane WV, Haymond MW, Dunger D, et al. Expanding treatment options for youth with type 2 diabetes: current problems and proposed solutions: a white paper from the NICHD Diabetes Working Group. Diabetes Care. 2016;39(3):323–9.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  1. 1.Department of PediatricsSt. Antonius HospitalUtrechtThe Netherlands
  2. 2.Department of Clinical PharmacySt Antonius HospitalUtrechtThe Netherlands
  3. 3.Division of Systems Biomedicine and PharmacologyLACDR, Leiden UniversityLeidenThe Netherlands

Personalised recommendations